The omicron subvariant BA.2 is continuing to gain ground in the U.S., according to Covid-19 tests sequenced over the last two weeks.
Helix, a San Diego-based genomics firm, has been watching the BA.2 variant since it first popped up in the U.S. in early January. Although it was initially slow to take hold, Helix now estimates that 50% to 70% of all Covid cases nationwide are BA.2.
Read More: BA.2 Variant Takes Hold in U.S. as New York Cases Start to Climb
Will Lee, Helix’s chief science officer, said this type of surveillance is essential and can help arm the U.S. health care system against future variants.